Real-world experience of IL-17Ai drug survival in a large cohort of axial spondyloarthritis and psoriatic arthritis.
Jake WeddellNaw Ra Aung DinStephanie Rose HarrisonXabier MichelenaDennis G McGonagleAndrew J BarrClaire VandeveldeJane FreestonHelena Marzo-OrtegaPublished in: Rheumatology advances in practice (2024)
This is the first study, to our knowledge, to analyse and compare real-world IL-17Ai drug survival in patients with axSpA and PsA from a single centre. We demonstrate that there is no difference in IL-17Ai survival rates and no relationship between diagnosis and drug survival. These results contribute to the body of real-world evidence confirming the role of IL-17Ai in the management of axSpA and PsA.